Showing results (391-400 of 458) with videos related to
Sort By:
Pageof 46
European Urology Focus|June 5, 2024
Final Results from SAUL, a Single-arm International Study of Atezolizumab in Unselected Patients with Pretreated Locally Advanced/Metastatic Urinary Tract CarcinomaCora N Sternberg, Yohann Loriot, Ernest Choy, et al.Nature Communications|December 4, 2020
Common germline-somatic variant interactions in advanced urothelial cancerAram Vosoughi, Tuo Zhang, Kyrillus S Shohdy, et al.European Urology Oncology|August 15, 2019
Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract CancersNieves Martinez Chanza, Lillian Werner, Elizabeth Plimack, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2023
External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate CancerSusan Halabi, Qian Yang, Akash Roy, et al.European Urology|January 19, 2021
Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT TrialRobert J Motzer, Paul Russo, Naomi Haas, et al.European Journal of Cancer (Oxford, England : 1990)|April 8, 2014
Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus PanelJohn M Fitzpatrick, Joaquim Bellmunt, Karim Fizazi, et al.The Prostate|November 16, 2022
Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancerChristopher T Su, Emily Nizialek, Jacob E Berchuck, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2022
FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA ExpressionCora N Sternberg, Daniel P Petrylak, Joaquim Bellmunt, et al.BJU International|November 14, 2013
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinomaGregory R Pond, Neeraj Agarwal, Joaquim Bellmunt, et al.JAMA Oncology|August 26, 2016
Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail StudyEllen S de Morrée, Nicholas J Vogelzang, Daniel P Petrylak, et al.Pageof 46